Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials
ABSTRACT Many patients with borderline personality disorder receive pharmacological treatment, but there is uncertainty about the usefulness of such therapies.
To evaluate the evidence of effectiveness of pharmacotherapy in treating different facets of the psychopathology of borderline personality disorder.
A Cochrane Collaboration systematic review and meta-analysis of randomised comparisons of drug v. placebo, drug v. drug, or single drug v. combined drug treatment in adult patients with borderline personality disorder was conducted. Primary outcomes were overall disorder severity as well as specific core symptoms. Secondary outcomes comprised associated psychiatric pathology and drug tolerability.
Twenty-seven trials were included in which first- and second-generation antipsychotics, mood stabilisers, antidepressants and omega-3 fatty acids were tested. Most beneficial effects were found for the mood stabilisers topiramate, lamotrigine and valproate semisodium, and the second-generation antipsychotics aripiprazole and olanzapine. However, the robustness of findings is low, since they are based mostly on single, small studies. Selective serotonin reuptake inhibitors so far lack high-level evidence of effectiveness.
The current evidence from randomised controlled trials suggests that drug treatment, especially with mood stabilisers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of borderline personality disorder. Pharmacotherapy should therefore be targeted at specific symptoms.
- SourceAvailable from: Andrew M Chanen
[Show abstract] [Hide abstract]
- "There is a paucity of useful pharmacotherapies that might be used independent of or as a complement to psychosocial treatment programs. The Cochrane group has identified 33 RCTs of pharmacotherapeutic interventions for adults with BPD (Stoffers & Lieb, 2015; Stoffers et al., 2010) as well as second-generation antipsychotics, mood stabilizers, and omega-3 PUFAs as promising agents. Other agents of interest that have yet to be formally tested in RCTs include those targeting N-methyl-D-aspartate signaling, and neuropeptides such as opioids and oxytocin (Bateman et al., 2015). "
ABSTRACT: Although borderline personality disorder (BPD) usually has its onset in young people, its diagnosis and treatment is often delayed. The past 2 decades have seen a rapid increase in evidence establishing that BPD can be diagnosed before 18 years of age and that BPD in young people is both continuous with BPD in adults and more notable for its similarities than for any differences. This knowledge has led to the first wave of controlled treatment trials, which have established that early intervention through appropriate BPD diagnosis and treatment leads to clinically meaningful improvements for patients. However, there is still much work to do in terms of treatment development and innovation and overcoming challenges to successful translation of evidence into practice. To advance early intervention for BPD, access to evidence-based treatments needs to improve, the variety of available treatments (including novel pharmacotherapies) needs to increase, treatments need to be matched to individual development and to the phase and stage of disorder, and workforce development strategies need to update knowledge, culture, and practice in relation to BPD in young people. © 2015 Wiley Periodicals, Inc.Journal of Clinical Psychology 07/2015; DOI:10.1002/jclp.22205 · 2.12 Impact Factor
[Show abstract] [Hide abstract]
- "On one hand, the psychiatrists used all types of medication for nearly every patient, but on the other they stated that they expected a definite improvement only in a quarter of the treated patients. In addition, Table 2 Medication in borderline personality disorder treatment: group of psychiatrists in this study vs. Cochrane systematic review (Lieb et al., 2010) Type of medication Psychiatrists in this study Cochrane review (based on 27 studies, with 1714 participants in total) "
ABSTRACT: Pharmacotherapy still seems to play a major role in the treatment of patients suffering from borderline personality disorder (BPD). However, little is known about psychiatrists' detailed perspective on indication and significance of medication. A total of 233 psychiatrists in the city of Munich and in Upper Bavaria were asked by questionnaire about their treatment habits in the medical treatment of patients with BPD. One hundred and forty-one psychiatrists answered the questionnaire (60.5%). In total, 94% of BPD patients were treated with psychotropic medication. Psychiatrists predominantly saw an indication to prescribe antidepressants (98%), followed by antipsychotics, mood stabilizers, and benzodiazepines. Citalopram/escitalopram and quetiapine were mentioned most frequently. The results are discussed in conjunction with the international guidelines for the treatment of BPD.International Clinical Psychopharmacology 07/2014; 29(4):224-228. DOI:10.1097/YIC.0000000000000021 · 3.10 Impact Factor
[Show abstract] [Hide abstract]
- ", but has not yet responded to a challenge from a Cochrane systematic review that followed shortly afterwards that reached different conclusions [Lieb et al. 2010]. "
ABSTRACT: The growing worldwide use of pharmaceuticals is managed in some countries by a regulatory system which sharply divides legal use into licensed and unlicensed categories. We examine how for the range of psychotropics this simultaneously restricts the possible benefits to patients, prescribers and producers in some domains, while failing to manage the risks in others. A more flexible system, which shares at an earlier stage experience and evidence on benefits and risks in patients, previously marginalized on the grounds of age, diagnosis or comorbidity, would aid the development of safer, more effective 'real-world prescribing'. Practical recommendations are made for a new model of research and prescribing governance, to enable more effective repurposing of these treatments.Therapeutic Advances in Psychopharmacology 08/2013; 3(4):233-43. DOI:10.1177/2045125312472530 · 1.53 Impact Factor